273 results on '"Weiner, D. B."'
Search Results
2. DNA vaccine cocktail expressing genotype A and C HBV surface and consensus core antigens generates robust cytotoxic and antibody responses in mice and Rhesus macaques
- Author
-
Obeng-Adjei, N, Hutnick, N A, Yan, J, Chu, J S, Myles, D J F, Morrow, M P, Sardesai, N Y, and Weiner, D B
- Published
- 2013
- Full Text
- View/download PDF
3. Synthetic DNA immunogen encoding hepatitis B core antigen drives immune response in liver
- Author
-
Obeng-Adjei, N, Choo, D K, Saini, J, Yan, J, Pankhong, P, Parikh, A, Chu, J S, and Weiner, D B
- Published
- 2012
- Full Text
- View/download PDF
4. Molecular adjuvant HMGB1 enhances anti-influenza immunity during DNA vaccination
- Author
-
Fagone, P, Shedlock, D J, Bao, H, Kawalekar, O U, Yan, J, Gupta, D, Morrow, M P, Patel, A, Kobinger, G P, Muthumani, K, and Weiner, D B
- Published
- 2011
- Full Text
- View/download PDF
5. Prototype development and preclinical immunogenicity analysis of a novel minimally invasive electroporation device
- Author
-
Broderick, K E, Shen, X, Soderholm, J, Lin, F, McCoy, J, Khan, A S, Yan, J, Morrow, M P, Patel, A, Kobinger, G P, Kemmerrer, S, Weiner, D B, and Sardesai, N Y
- Published
- 2011
- Full Text
- View/download PDF
6. Plasmids encoding the mucosal chemokines CCL27 and CCL28 are effective adjuvants in eliciting antigen-specific immunity in vivo
- Author
-
Kutzler, M A, Kraynyak, K A, Nagle, S J, Parkinson, R M, Zharikova, D, Chattergoon, M, Maguire, H, Muthumani, K, Ugen, K, and Weiner, D B
- Published
- 2010
- Full Text
- View/download PDF
7. Hydrodynamic immunization leads to poor CD8 T-cell expansion, low frequency of memory CTLs and ineffective antiviral protection
- Author
-
Obeng-Adjei, N, Choo, D K, and Weiner, D B
- Published
- 2013
- Full Text
- View/download PDF
8. Regression of subcutaneous B16 melanoma tumors after intratumoral delivery of an IL-15-expressing plasmid followed by in vivo electroporation
- Author
-
Ugen, K E, Kutzler, M A, Marrero, B, Westover, J, Coppola, D, Weiner, D B, and Heller, R
- Published
- 2006
- Full Text
- View/download PDF
9. HIV DNA Vaccination: Advances and Experiences
- Author
-
Fernando, K. P., Muthumani, K., Zhang, D., Kudchodkar, S., and Weiner, D. B.
- Published
- 2001
- Full Text
- View/download PDF
10. Macaques co-immunized with SIVgag/pol-HIVenv and IL-12 plasmid have increased cellular responses
- Author
-
Robinson, T. M., Sidhu, M. K., Pavlakis, G. N., Felber, B. K., Silvera, P., Lewis, M. G., Eldridge, J., Weiner, D. B., and Boyer, J. D.
- Published
- 2007
11. Inclusion of Vpr accessory gene in a plasmid vaccine cocktail markedly reduces Nef vaccine effectiveness in vivo resulting in CD4 cell loss and increased viral loads in rhesus macaques
- Author
-
Muthumani, K., Bagarazzi, M., Conway, D., Hwang, D. S., Ayyavoo, V., Zhang, D., Manson, K., Kim, J., Boyer, J., and Weiner, D. B.
- Published
- 2002
12. Chemokine-adjuvanted electroporated DNA vaccine induces substantial protection from simian immunodeficiency virus vaginal challenge.
- Author
-
Kutzler, M A, Wise, M C, Hutnick, N A, Moldoveanu, Z, Hunter, M, Reuter, M A, Yuan, S, Yan, J, Ginsberg, A A, Sylvester, A, Pahar, B, Carnathan, D G, Kathuria, N, Khan, A S, Montefiori, D, Sardesai, N Y, Betts, M R, Mestecky, J, Marx, P A, and Weiner, D B
- Published
- 2016
- Full Text
- View/download PDF
13. Human immunodeficiency virus type 1 (HIV-1) Vpr-regulated cell death: insights into mechanism.
- Author
-
Muthumani, K, Choo, A Y, Premkumar, A, Hwang, D S, Thieu, K P, Desai, B M, and Weiner, D B
- Subjects
HIV ,HIV infections ,APOPTOSIS ,CELL death ,CELL cycle ,GLUCOCORTICOID receptors ,MITOCHONDRIAL membranes ,NF-kappa B ,HEAT shock proteins - Abstract
The destruction of CD4
+ T cells and eventual induction of immunodeficiency is a hallmark of the human immunodeficiency virus type 1 infection (HIV-1). However, the mechanism of this destruction remains unresolved. Several auxiliary proteins have been proposed to play a role in this aspect of HIV pathogenesis including a 14 kDa protein named viral protein R (Vpr). Vpr has been implicated in the regulation of various cellular functions including apoptosis, cell cycle arrest, differentiation, and immune suppression. However, the mechanism(s) involved in Vpr-mediated apoptosis remains unresolved, and several proposed mechanisms for these effects are under investigation. In this review, we discuss the possibility that some of these proposed pathways might converge to modulate Vpr's behavior. Further, we also discuss caveats and future directions for investigation of the interesting biology of this HIV accessory gene.Cell Death and Differentiation (2005) 12, 962–970. doi:10.1038/sj.cdd.4401583 Published online 15 April 2005 [ABSTRACT FROM AUTHOR]- Published
- 2005
- Full Text
- View/download PDF
14. Philippe Pinel's "Memoir on Madness" of December 11, 1794: a fundamental text of modern psychiatry.
- Author
-
Weiner, D B
- Subjects
- *
HISTORY of human rights , *PSYCHIATRIC diagnosis , *MENTAL illness treatment , *HISTORY of psychiatry , *PSYCHIATRIC hospitals , *COMPARATIVE studies , *HISTORY , *RESEARCH methodology , *MEDICAL cooperation , *PSYCHOTHERAPY , *RESEARCH , *EVALUATION research - Abstract
Philippe Pinel's "Memoir on Madness" can now be precisely dated. It was read to the Society for Natural History in Paris on Dec. 11, 1794, soon after the fall of the Jacobin dictatorship. It is thus a political document, an appeal to the Revolutionary government to build asylums where the mentally ill could be decently treated. It is translated here for the first time. Philippe Pinel (1745-1826) served as "physician of the infirmaries" at Bicêtre, the public hospice for men near Paris, from 1793 to 1795. In the "Memoir on Madness" he explains his "psychologic treatment," the principles of the humane method that made him the founder of psychiatry in France. Pinel states that mental illness is often curable. To arrive at a diagnosis, the physician must carefully observe a patient's behavior, interview him, listen carefully, and take notes. He must understand the natural history of the disease and the precipitating event and write an accurate case history. Diagnosis and prognosis can then be made. Periodic patterns of mental illness can be helpful for therapy. Usually only one faculty is affected. Patients with delusions may be malicious or murderous. They may have to be restrained; it was Pinel's assistant, Jean Baptiste Pussin, who removed the chains from the insane men at Bicêtre Hospice in 1797 and replaced them with strait-jackets. Pinel followed suit at the Salpêtrière, the public hospice for women, 3 years later. Pinel here states that one must "dominate agitated madmen while respecting human rights." [ABSTRACT FROM AUTHOR]
- Published
- 1992
- Full Text
- View/download PDF
15. Vertical transmission of human immunodeficiency virus type 1: seroreactivity by maternal antibodies to the carboxy region of the gp41 envelope glycoprotein.
- Author
-
Ugen, Kenneth E., Srikantan, Vasantha, Goedert, James J., Nelson, Robert P., Williams, William V., Weiner, David B., Ugen, K E, Srikantan, V, Goedert, J J, Nelson, R P Jr, Williams, W V, and Weiner, D B
- Abstract
Maternal antibodies against the envelope glycoprotein of human immunodeficiency virus type 1 (HIV-1) have previously been suggested to be important in influencing the rate of vertical transmission. In this study, serum antibody responses in mothers who did or did not transmit HIV-1 infection to their children were measured against the carboxy region of the transmembrane envelope glycoprotein gp41. Results indicate significantly higher binding reactivity of nontransmitter mothers compared with transmitters to three peptides spanning amino acids 771–810 and 841–856. In addition, high neutralization titers in maternal sera against HIV-1MN were associated with a non-transmission status. This is the initial report demonstrating a correlation between maternal antibody binding to epitopes within the carboxy region of gp41 envelope glycoprotein and lack of vertical transmission. Immunodetection that identifies antibodies to these regions in gp41 could therefore be considered a strategy to assess the risk of vertical transmission of HIV-1. [ABSTRACT FROM PUBLISHER]
- Published
- 1997
16. Diagnosis and prediction of pediatric HIV-1 infection and AIDS: current status.
- Author
-
Ugen, Kenneth E., Von Feldt, Joan M., Weiner, David B., Ziegner, Ulrike H. M., Ugen, K E, Von Feldt, J M, Weiner, D B, and Ziegner, U H
- Published
- 1994
- Full Text
- View/download PDF
17. Expression and immune response to hepatitis C virus core DNA-based vaccine constructs.
- Author
-
Tokushige, K, Wakita, T, Pachuk, C, Moradpour, D, Weiner, D B, Zurawski, V R, and Wands, J R
- Published
- 1996
- Full Text
- View/download PDF
18. E-DNA IM or ID delivery prime enhances antibody and T cell responses following recombinant gp120 env boost.
- Author
-
Hutnick, N. A., Karuppiah, M., Pollara, J., Yan, J., Myles, D. J., Broderick, K., Morrow, M., Sardasai, N., Montefiori, D., Barnett, S., Ferrari, G., and Weiner, D. B.
- Subjects
T cells - Abstract
An abstract of the conference paper "E-DNA IM or ID delivery prime enhances antibody and T cell responses following recombinant gp120 env boost," by J. Yan and colleagues is presented.
- Published
- 2012
- Full Text
- View/download PDF
19. Comparison of cellular and humoral immune responses induced by primary, consensus or mosaic HIV-1 Env DNA vaccines.
- Author
-
Yan, J., Pankhong, P., Khan, A. S., Sardesai, N. Y., and Weiner, D. B.
- Subjects
DNA vaccines - Abstract
An abstract of the research paper on the comparison of cellular and humoral immune responses related to HIV-1 Env DNA vaccines by J. Yan and colleagues at the AIDS Vaccine 2012 in Boston, Massachusetts is presented.
- Published
- 2012
- Full Text
- View/download PDF
20. Potent cellular immune responses after therapeutic immunization of HIV-positive patients with the PENNVAX-B DNA vaccine in a Phase I Trial.
- Author
-
Tebas, P., Ramirez, L., Morrow, M. P., Yan, J., Shah, D., J. Lee, Weiner, D. B., Boyer, J., Bagarazzi, M., and Sardesai, N. Y.
- Subjects
IMMUNIZATION - Abstract
An abstract of the research paper "Potent cellular immune responses after therapeutic immunization of HIV-positive patients with the PENNVAX-B DNA vaccine in a Phase I Trial," by P. Tebas and colleagues is presented.
- Published
- 2012
- Full Text
- View/download PDF
21. Improved systemic and mucosal antibody responses with a CCR10 ligand adjuvant.
- Author
-
Hutnick, N., Myles, D. J., Ginsberg, A., Khan, A. S., Yan, J., Moldoveanu, Z., Mestecky, J., Marx, P. A., Kutzler, M., and Weiner, D. B.
- Subjects
MUCOUS membranes - Abstract
An abstract of the research paper "Improved systemic and mucosal antibody responses with a CCR10 ligand adjuvant," by N. Hutnick and colleagues is presented.
- Published
- 2012
- Full Text
- View/download PDF
22. Robust antibody and cellular responses with an improved DNA vaccine alone.
- Author
-
Hutnick, N., Myles, D. J., Muthumani, K., Morrow, M., Yan, J., Khan, A. S., Sardasai, N. Y., and Weiner, D. B.
- Subjects
DNA vaccines - Abstract
An abstract of the conference paper "Robust Antibody and Cellular responses With an Improved DNA Vaccine Alone" by N. Hutnick and colleagues is presented.
- Published
- 2012
- Full Text
- View/download PDF
23. DNA vaccines expressing conserved elements provide potent and broad immune responses.
- Author
-
Pavlakis, G. N., Kulkarni, V., Valentin, A., Rosati, M., Sardesai, N. Y., Mothe, B., Brander, C., LeGall, S., Weiner, D. B., Rolland, M., Mullins, J. I., and Felber, B. K.
- Subjects
DNA vaccines - Abstract
An abstract of the conference paper "DNA vaccines expressing conserved elements provide potent and broad immune responses" by G.N. Pavlakis and colleagues is presented.
- Published
- 2012
- Full Text
- View/download PDF
24. Minimally invasive and surface electroporation delivery of DNA vaccines for the induction of robust humoral immune responses against HIV antigens.
- Author
-
Sardesai, N. Y., Khan, A. S., McCoy, J., Lin, F., Mendoza, J. M., M. Yang, J. Yan, Hutnick, N., Muthumani, K., Weiner, D. B., and Broderick, K. E.
- Subjects
ELECTROPORATION - Abstract
An abstract of the conference paper "Minimally invasive and surface electroporation delivery of DNA vaccines for the induction of robust humoral immune responses against HIV antigens," by N. Y. Sardesai and colleagues is presented.
- Published
- 2012
- Full Text
- View/download PDF
25. CCR10 expression is required for the adjuvant activity of the mucosal chemokine CCL28 when delivered in the context of an HIV-1 Env DNA vaccine.
- Author
-
Gary EN, Kathuria N, Makurumidze G, Curatola A, Ramamurthi A, Bernui ME, Myles D, Yan J, Pankhong P, Muthumani K, Haddad E, Humeau L, Weiner DB, and Kutzler MA
- Subjects
- Animals, HIV Antibodies immunology, HIV-1 immunology, Immunity, Mucosal, Immunoglobulin A immunology, Immunoglobulin G blood, Mice, Mucous Membrane immunology, env Gene Products, Human Immunodeficiency Virus immunology, AIDS Vaccines administration & dosage, Adjuvants, Immunologic administration & dosage, Chemokines, CC administration & dosage, Receptors, CCR10 genetics, Vaccines, DNA administration & dosage
- Abstract
An effective prophylactic vaccine targeting HIV must induce a robust humoral response and must direct the bulk of this response to the mucosa-the primary site of HIV transmission. The chemokine, CCL28, is secreted by epithelial cells at mucosal surfaces and recruits' cells expressing its receptor CCR10. CCR10 is predominantly expressed by IgA + ASCs. We hypothesized that co-immunization with plasmid DNA encoding consensus envelope antigens with plasmid-encoded CCL28 would enhance anti-HIV IgA responses at mucosal surfaces. Indeed, animals receiving pCCL28 and pEnvA/C had significantly increased HIV-specific IgA in fecal extract. Surprisingly, CCL28 co-immunization induced a significant increase in anti-HIV IgG in the serum in mice compared to those receiving pEnvA/C alone. These robust antibody responses were not associated with changes in the frequency of germinal center B cells but depended upon the expression of CCR10, as these responses we abolished in CCR10-deficient animals. Finally, immunization with CCL28 led to increased frequencies in HIV-specific CCR10 + and CCR10 + IgA + B cells in the small intestine and Peyer's patches of vaccinated animals as compared to those receiving pEnvA/C alone. These data indicate that CCL28 administration can enhance antigen-specific humoral responses systemically and at mucosal surfaces., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2020. Published by Elsevier Ltd.)
- Published
- 2020
- Full Text
- View/download PDF
26. Immunogenicity of a novel enhanced consensus DNA vaccine encoding the leptospiral protein LipL45.
- Author
-
Vijayachari P, Vedhagiri K, Mallilankaraman K, Mathur PP, Sardesai NY, Weiner DB, Ugen KE, and Muthumani K
- Subjects
- Animals, Antibodies, Bacterial blood, Bacterial Outer Membrane Proteins genetics, Bacterial Vaccines administration & dosage, Bacterial Vaccines genetics, Electroporation, Female, Injections, Intramuscular, Interferon-gamma metabolism, Interleukin-12 metabolism, Leukocytes, Mononuclear immunology, Lipoproteins genetics, Mice, Inbred BALB C, Th1 Cells immunology, Vaccines, DNA administration & dosage, Vaccines, DNA genetics, Vaccines, Synthetic administration & dosage, Vaccines, Synthetic genetics, Vaccines, Synthetic immunology, Bacterial Outer Membrane Proteins immunology, Bacterial Vaccines immunology, Leptospirosis prevention & control, Lipoproteins immunology, Vaccines, DNA immunology
- Abstract
Leptospirosis is a bacterial zoonotic disease caused by an infection with a spirochete belonging to the genus Leptospira. In animals, leptospirosis displays a wide range of pathologies, including fever, abortion, icterus, and uveitis. Conversely, infection in humans is associated with multi-organ injury, resulting in an increased rate of fatalities. Pathogenic leptospires are able to translocate through cell monolayers at a rate significantly greater than that of non-pathogenic leptospires. Thus, vaccine approaches have been focused on targeting bacterial motility, lipopolysaccharides (LPSs), lipoproteins, outer-membrane proteins (OMPs) and other potential virulence factors. Previous studies have indicated that leptospiral proteins elicit long-lasting immunological memory in infected humans. In the study reported here, the efficacy of a synthetic consensus DNA vaccine developed against the Leptospira membrane lipoprotein LipL45 was tested. After in vivo electroporation (EP) mediated intramuscular immunization with a synthetic LipL45 DNA vaccine (pLipL45) immunized mice developed a significant cellular response along with the development of anti-LipL45-specific antibodies. Specifically, the pLipL45 vaccine induced a significant Th1 type immune response, indicated by the higher production of IL-12 and IFN-γ cytokines. The results presented here are the first demonstration that a LipL45 based DNA immunogen has potential as a anti-Leptospira vaccine.
- Published
- 2015
- Full Text
- View/download PDF
27. Inducing humoral and cellular responses to multiple sporozoite and liver-stage malaria antigens using exogenous plasmid DNA.
- Author
-
Ferraro B, Talbott KT, Balakrishnan A, Cisper N, Morrow MP, Hutnick NA, Myles DJ, Shedlock DJ, Obeng-Adjei N, Yan J, Kayatani AK, Richie N, Cabrera W, Shiver R, Khan AS, Brown AS, Yang M, Wille-Reece U, Birkett AJ, Sardesai NY, and Weiner DB
- Subjects
- Animals, Cell Line, DNA, Protozoan genetics, Female, Immunity, Cellular, Immunity, Humoral, Macaca mulatta, Malaria, Falciparum immunology, Malaria, Falciparum parasitology, Mice, Mice, Inbred BALB C, Antigens, Protozoan immunology, DNA, Protozoan immunology, Liver parasitology, Plasmids genetics, Plasmodium falciparum physiology, Sporozoites immunology
- Abstract
A vaccine candidate that elicits humoral and cellular responses to multiple sporozoite and liver-stage antigens may be able to confer protection against Plasmodium falciparum malaria; however, a technology for formulating and delivering such a vaccine has remained elusive. Here, we report the preclinical assessment of an optimized DNA vaccine approach that targets four P. falciparum antigens: circumsporozoite protein (CSP), liver stage antigen 1 (LSA1), thrombospondin-related anonymous protein (TRAP), and cell-traversal protein for ookinetes and sporozoites (CelTOS). Synthetic DNA sequences were designed for each antigen with modifications to improve expression and were delivered using in vivo electroporation (EP). Immunogenicity was evaluated in mice and nonhuman primates (NHPs) and assessed by enzyme-linked immunosorbent assay (ELISA), gamma interferon (IFN-γ) enzyme-linked immunosorbent spot (ELISpot) assay, and flow cytometry. In mice, DNA with EP delivery induced antigen-specific IFN-γ production, as measured by ELISpot assay and IgG seroconversion against all antigens. Sustained production of IFN-γ, interleukin-2, and tumor necrosis factor alpha was elicited in both the CD4(+) and CD8(+) T cell compartments. Furthermore, hepatic CD8(+) lymphocytes produced LSA1-specific IFN-γ. The immune responses conferred to mice by this approach translated to the NHP model, which showed cellular responses by ELISpot assay and intracellular cytokine staining. Notably, antigen-specific CD8(+) granzyme B(+) T cells were observed in NHPs. Collectively, the data demonstrate that delivery of gene sequences by DNA/EP encoding malaria parasite antigens is immunogenic in animal models and can harness both the humoral and cellular arms of the immune system.
- Published
- 2013
- Full Text
- View/download PDF
28. IL-4 increases Simian immunodeficiency virus replication despite enhanced SIV immune responses in infected rhesus macaques.
- Author
-
Boyer JD, Nath B, Schumann K, Curley E, Manson K, Kim J, and Weiner DB
- Subjects
- Animals, Antibodies, Viral blood, CD4 Lymphocyte Count, Humans, Immunization, Interleukin-4 administration & dosage, Interleukin-4 genetics, Lymphocyte Activation, Macaca mulatta, Plasmids genetics, SAIDS Vaccines administration & dosage, Simian Acquired Immunodeficiency Syndrome prevention & control, Simian Acquired Immunodeficiency Syndrome virology, Viral Load, Interleukin-4 immunology, SAIDS Vaccines immunology, Simian Acquired Immunodeficiency Syndrome immunology, Simian Immunodeficiency Virus immunology, Simian Immunodeficiency Virus physiology, Virus Replication
- Abstract
It is widely believed that a Th1 type CD4 response is critical for enhancement of CD8 immunity and for controlling HIV-1 infection. Th2 type responses, such as what might be seen in a chronic parasitic infection, would sacrifice cellular immunity and thus benefit the virus at the expense of the host. However, there has been little direct examination of the hypothesis in a primate model system. Accordingly, the simian immunodeficiency virus (SIV) infected rhesus macaque model was used to investigate the impact of immunisation with SIV expressing DNA constructs and co-injection with IL-4 on the SIV specific immunological responses, lymphocyte cell counts, as well as the impact on viral load. IL-4 is a Th2 type cytokine, which enhances antibody production and inhibits a CD4 Th1 phenotype. Rhesus macaques were infected with 10 AID50 of SIVmac239 and treated with 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) 9 weeks post-infection. During PMPA treatment, animals were immunised with plasmids that expressed the SIV proteins, env, rev, gag and pol. In addition, they were immunised with a construct that encoded the gene for IL-4. IL-4 co-immunisation increased the neutralizing antibody titres in this group. Importantly, the viral loads in animals vaccinated with IL-4 expressing plasmid increased during the immunisation regimens despite the higher neutralizing antibody titres. In addition, neutralizing antibodies did not correlate with viral set point prior to PMPA treatment, however, there was a correlation between viral loads and antibody titres following the treatment with PMPA. Antibody titres decreased following the suppression of viral load. Importantly, vaccination in the absence of IL-4 protected CD4 levels without increasing viral load. The data support the hypothesis that inappropriate immune bias toward a Th2 pathway would ultimately enhance disease progression.
- Published
- 2002
- Full Text
- View/download PDF
29. Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer's disease-associated beta-amyloid 1-42 peptide.
- Author
-
Dickey CA, Morgan DG, Kudchodkar S, Weiner DB, Bai Y, Cao C, Gordon MN, and Ugen KE
- Subjects
- Amino Acid Sequence, Amyloid beta-Peptides chemistry, Amyloid beta-Peptides immunology, Animals, Enzyme-Linked Immunosorbent Assay, Immunoglobulins classification, Mice, Molecular Sequence Data, Peptide Fragments chemistry, Peptide Fragments immunology, Sequence Homology, Amino Acid, Amyloid beta-Peptides administration & dosage, Antibody Formation, Antibody Specificity, Peptide Fragments administration & dosage, Vaccines administration & dosage
- Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by overproduction of beta-amyloid (Abeta), which is formed from amyloid precursor protein (APP), with the subsequent pathologic deposition of Abeta in regions of the brain important for memory and cognition. Recently, vaccination of murine models of AD that exhibit Abeta deposition has halted or delayed the usual progression of the pathology of AD. Our group has demonstrated that vaccination of a doubly transgenic mouse model (expressing mutant APP and presenilin-1) with the Abeta 1-42 peptide protects these mice from the memory deficits they would ordinarily develop. This report further characterizes the Abeta 1-42 peptide vaccine in mice. Anti-Abeta response time course analysis indicated that at least three vaccinations (each 100 microg) were necessary to elicit a significant anti-Abeta titer. Subsequent vaccinations resulted in half-maximal antibody titers of at least 10,000, and these titers were maintained for at least 5 months after the final boost. Peptide binding competition studies indicated that the highest humoral responses are generated against the N terminus of the Abeta peptide. Also, measurement of specific murine Ig isotypes in Abeta-vaccinated mice demonstrated a predominant IgG(1) and IgG(2b) response, suggesting a type 2 (Th2) T-helper cell immune response, which drives humoral immunity. Finally, lymphocyte proliferation assay experiments using Abeta peptides and splenocytes from vaccinated mice demonstrated that the vaccine specifically stimulates T-cell epitopes present within the Abeta peptide.
- Published
- 2001
- Full Text
- View/download PDF
30. HIV-1 Vpr transactivates LTR-directed expression through sequences present within -278 to -176 and increases virus replication in vitro.
- Author
-
Vanitharani R, Mahalingam S, Rafaeli Y, Singh SP, Srinivasan A, Weiner DB, and Ayyavoo V
- Subjects
- Gene Products, vpr genetics, Glucocorticoids pharmacology, HIV Enhancer, HIV Long Terminal Repeat genetics, HIV-1 chemistry, HIV-1 pathogenicity, HeLa Cells, Humans, Luciferases, Mutation, Response Elements, Virus Replication, vpr Gene Products, Human Immunodeficiency Virus, Gene Products, vpr physiology, HIV Infections virology, HIV-1 physiology, Trans-Activators physiology
- Abstract
Human immunodeficiency virus type 1 (HIV-1) Vpr, a 14-kDa virion-associated protein, plays an important role in the viral life cycle. Using a panel of truncated HIV-1 LTR-CAT constructs and Vpr expression plasmid, we have identified sequences from nucleotide -278 to -176 in LTR as Vpr-mediated transactivation domain. This region includes the glucocorticoid response element (GRE) in HIV-1 LTR. Transactivation by Vpr was noted with the HIV-1 LTR reporter constructs containing CAT or luciferase. A similar effect was also observed with a construct in which the GRE motif was linked to CAT. Studies involving Vpr mutants identified that helical domains I and III, and amino acid residues at G75 and C76, are responsible for GRE-mediated LTR transactivation. The transactivation function of Vpr is independent of its cell cycle arrest activity. Further, viral replication studies indicated that Vpr-mediated increase in viral replication is directly correlated with the ability of Vpr to transactivate HIV-1 LTR. The results presented here demonstrate that Vpr activates HIV-1 LTR through the host GR pathway and suggest that an intact GRE in the LTR is critical for Vpr activity., (Copyright 2001 Academic Press.)
- Published
- 2001
- Full Text
- View/download PDF
31. Induction of potent Th1-type immune responses from a novel DNA vaccine for West Nile virus New York isolate (WNV-NY1999).
- Author
-
Yang JS, Kim JJ, Hwang D, Choo AY, Dang K, Maguire H, Kudchodkar S, Ramanathan MP, and Weiner DB
- Subjects
- Animals, Antigens, Viral immunology, Capsid immunology, Cytokines analysis, Disease Models, Animal, Female, Mice, Mice, Inbred BALB C, Muscles immunology, West Nile virus isolation & purification, T-Lymphocytes, Cytotoxic immunology, Th1 Cells immunology, Vaccines, DNA administration & dosage, Viral Vaccines administration & dosage, West Nile Fever prevention & control, West Nile virus immunology
- Abstract
West Nile virus (WNV) is a vectorborne pathogen that induces brain inflammation and death. Recently, confirmed cases of infection and deaths have occurred in the United States Mid-Atlantic region. In this study, a DNA vaccine encoding the WNV capsid protein was constructed, and the in vivo immune responses generated were investigated in DNA vaccine-immunized mice. Antigen-specific humoral and cellular immune responses were observed, including a potent induction of antigen-specific Th1 and cytotoxic T lymphocyte responses. Strong induction of Th1-type immune responses included high levels of antigen-specific elaboration of the Th1-type cytokines interferon-gamma and interleukin-2 and beta-chemokines RANTES (regulated upon activation, normal T cell-expressed and secreted) and macrophage inflammatory protein-1beta. Dramatic infiltration of CD4 and CD8 T cells and macrophages also was observed at the muscle injection site. These results support the potential utility of this method as a tool for developing immunization strategies for WNV and other emerging pathogens.
- Published
- 2001
- Full Text
- View/download PDF
32. Induction of immune responses and safety profiles in rhesus macaques immunized with a DNA vaccine expressing human prostate specific antigen.
- Author
-
Kim JJ, Yang JS, Nottingham LK, Tang W, Dang K, Manson KH, Wyand MS, Wilson DM, and Weiner DB
- Subjects
- Animals, Blood Cell Count, Cancer Vaccines administration & dosage, Cancer Vaccines toxicity, Dose-Response Relationship, Immunologic, Humans, Interferon-gamma metabolism, Kidney Function Tests, Liver Function Tests, Lymphocyte Activation, Macaca mulatta, Male, Prostate drug effects, Safety, Th1 Cells immunology, Th1 Cells metabolism, Vaccination adverse effects, Vaccines, DNA administration & dosage, Vaccines, DNA toxicity, Vaccines, Synthetic administration & dosage, Vaccines, Synthetic immunology, Vaccines, Synthetic toxicity, Antigens, Neoplasm immunology, Cancer Vaccines immunology, Prostate-Specific Antigen immunology, Vaccines, DNA immunology
- Abstract
Prostate specific antigen (PSA) is a widely used marker for prostate cancer, which is secreted by normal prostate cells at low levels, but is produced more substantially by cancer cells. We have previously reported on the use of a DNA vaccine construct that encodes for human PSA gene to elicit host immune responses against cells producing PSA. DNA immunization strategy delivers DNA constructs encoding for a specific immunogen into the host, who becomes the in vivo protein source for the production of antigen. This antigen then is the focus of the resulting immune response. In this study, we examine the induction of immune responses and safety profiles in rhesus macaques immunized with DNA-based PSA vaccine. We observed induction of PSA-specific humoral response as well as positive PSA-specific lymphoproliferative (LPA) response in the vaccinated macaques. We also observed that the stimulated T cells from the PSA-immunized rhesus macaques produced higher levels of Th1 type cytokine IFN-gamma than the control vector immunized animals. On the other hand, DNA immunization did not result in any adverse effects in the immunized macaques, as indicated by complete blood counts, leukocyte differentials and hepatic and renal chemistries. The macaques appeared healthy, without any physical signs of toxicity throughout the observation period. In addition, we did not observe any adverse effect on the vaccination site. The apparent safety and immunogenecity of DNA immunization in this study suggest that further evaluation of this vaccination strategy is warranted.
- Published
- 2001
- Full Text
- View/download PDF
33. Protection from immunodeficiency virus challenges in rhesus macaques by multicomponent DNA immunization.
- Author
-
Kim JJ, Yang JS, Nottingham LK, Lee DJ, Lee M, Manson KH, Wyand MS, Boyer JD, Ugen KE, and Weiner DB
- Subjects
- Animals, HIV-1 genetics, Humans, Macaca mulatta, AIDS Vaccines immunology, HIV-1 immunology, Simian Acquired Immunodeficiency Syndrome prevention & control, Simian Immunodeficiency Virus immunology, Vaccines, DNA immunology
- Abstract
Multicomponent DNA vaccines were used to elicit immune responses, which can impact viral challenge in three separate rhesus macaque models. Eight rhesus macaques were immunized with DNA vaccines for HIV env/rev and SIV gag/pol and were challenged intravenously with 10 animal infective doses (AID(50)) of cell-free SHIV IIIB. Three of eight immunized rhesus macaques were protected, exhibiting no detectable virus. Animals protected from nonpathogenic SHIVIIIB challenge were rested for extended periods of time and were rechallenged first with pathogenic SIV(mac239) and subsequently with pathogenic SHIV89.6P viruses. Following the pathogenic challenges, all three vaccinated animals were negative for viral coculture and antigenemia and were negative by PCR. In contrast, the control animals exhibited antigenemia by 2 weeks postchallenge and exhibited greater than 10 logs of virus/10(6) cells in limiting dilution coculture. The control animals exhibited CD4 cell loss and developed SIV-related wasting with high viral burden and subsequently failed to thrive. Vaccinated animals remained virus-negative and were protected from the viral load, CD4 loss, disease, and death. We observed strong Th1-type cellular immune responses in the protected macaques throughout the study, suggesting their important roles in protection. These studies support the finding that multicomponent DNA vaccines can directly impact viral replication and disease in a highly pathogenic challenge system, thus potentially broadening our strategies against HIV., (Copyright 2001 Academic Press.)
- Published
- 2001
- Full Text
- View/download PDF
34. Modulation of cellular responses by plasmid CD40L: CD40L plasmid vectors enhance antigen-specific helper T cell type 1 CD4+ T cell-mediated protective immunity against herpes simplex virus type 2 in vivo.
- Author
-
Sin JI, Kim JJ, Zhang D, and Weiner DB
- Subjects
- Adjuvants, Immunologic genetics, Administration, Intravaginal, Animals, CD40 Ligand genetics, Cell Movement immunology, Chemokines biosynthesis, Cytokines biosynthesis, Female, Genetic Vectors administration & dosage, Genetic Vectors chemical synthesis, Genetic Vectors immunology, Herpes Genitalis mortality, Humans, Immunity, Cellular genetics, Immunoglobulin G biosynthesis, Injections, Intramuscular, Lymphocyte Activation genetics, Mice, Mice, Inbred BALB C, Plasmids administration & dosage, Plasmids genetics, Vaccines, DNA administration & dosage, Vagina, Adjuvants, Immunologic therapeutic use, CD40 Ligand therapeutic use, Epitopes, T-Lymphocyte immunology, Herpes Genitalis immunology, Herpes Genitalis prevention & control, Herpesvirus 2, Human immunology, Plasmids immunology, Th1 Cells immunology
- Abstract
Engineering gene therapy vectors to modulate the immune response is an important goal. In this regard, costimulation of T cells is a critical determinant in immune activation. The costimulatory molecule CD40, expressed on antigen-presenting cells, is thought to interact with CD40 ligand (CD40L) expressed on activated CD4(+) or CD8(+) T cells to further drive interleukin-2 receptor (IL-2R) expression and antigen-specific T cell expansion necessary for both class II and class I responses. To compare the specific roles of these two costimulatory molecules in immune induction in a herpes simplex virus (HSV) model, we constructed plasmid DNAs expressing CD40 and CD40L, coimmunized these molecules with a gD plasmid vaccine, and then analyzed immune modulatory effects as well as protection against lethal HSV-2 challenge. We observed that gD-specific IgG production was unaffected by these molecules. However, a higher production of IgG2a isotype was induced by CD40L coinjection, suggesting that CD40L drives immune responses towards a helper T cell type 1 (Th1) phenotype. CD40L also enhanced Th cell proliferative responses and production of Th1-type cytokines (IL-2 and IFN-gamma) and beta-chemokines (RANTES and MIP-1alpha) from splenocytes. In contrast, CD40 showed slightly increasing effects on T cell proliferation responses and cytokine and chemokine production. When animals were challenged with a lethal dose of HSV-2, CD40L-coimmunized animals exhibited a significantly enhanced survival rate, as compared with CD40 coinjection or gD DNA vaccine alone. This enhanced protection appears to be mediated by Th1-type CD4(+) T cells, as determined by in vitro and in vivo T cell subset deletion. CD40L also promoted migration of CD4(+) T cells into the muscle sites. These studies demonstrate that CD40L can play an important role in protective antigen-specific immunity in a gene-based model system through increased expansion of the CD4(+) Th1 T cell subset in vivo.
- Published
- 2001
- Full Text
- View/download PDF
35. Modulation of antigen-specific cellular immune responses to DNA vaccination in rhesus macaques through the use of IL-2, IFN-gamma, or IL-4 gene adjuvants.
- Author
-
Kim JJ, Yang JS, Manson KH, and Weiner DB
- Subjects
- AIDS Vaccines genetics, AIDS Vaccines pharmacology, Animals, Antigens, Viral genetics, Gene Expression, Humans, In Vitro Techniques, Interferon-gamma genetics, Interleukin-2 genetics, Interleukin-4 genetics, Lymphocyte Activation, Macaca mulatta, SAIDS Vaccines genetics, SAIDS Vaccines pharmacology, Simian Immunodeficiency Virus genetics, Simian Immunodeficiency Virus immunology, T-Lymphocytes, Cytotoxic immunology, Vaccines, DNA genetics, Adjuvants, Immunologic genetics, Cytokines genetics, Immunity, Cellular, Vaccines, DNA pharmacology
- Abstract
Extensive experiments have shown DNA vaccines' ability to elicit immune responses in vivo in a safe and well-tolerated manner in several model systems, including rodents and non-human primates. As the DNA-based vaccine and immunotherapy approaches are being explored in humans, significant efforts have also been focused on further improving the immune potency of this technology. One strategy to enhance immune responses for DNA vaccines is the use of molecular or genetic adjuvants. These molecular adjuvant constructs (which encodes for immunologically important molecules such as cytokines) can be co-administered along with DNA vaccine constructs. Once delivered, these adjuvants have shown to modulate the magnitude and direction (humoral or cellular) of the vaccine-induced immune responses in rodent models. To date, however, there has been very little data reported from studies in primates. In this study, we examined the effects of cytokine gene adjuvants to enhance the level of cell-mediated immune responses in rhesus macaques. We co-immunized rhesus macaques with expression plasmids encoding for IL-2, IFN-gamma or IL-4 cytokines along with the DNA vaccine constructs encoding for HIV env/rev (pCEnv) and SIV gag/pol (pCSGag/pol) proteins. We observed that coadministration of IL-2 and IFN-gamma cDNA resulted in enhancement of antigen-specific T cell-mediated immune responses.
- Published
- 2001
- Full Text
- View/download PDF
36. Engineering enhancement of immune responses to DNA-based vaccines in a prostate cancer model in rhesus macaques through the use of cytokine gene adjuvants.
- Author
-
Kim JJ, Yang JS, Dang K, Manson KH, and Weiner DB
- Subjects
- Animals, Cell Division, DNA, Complementary metabolism, Enzyme-Linked Immunosorbent Assay, Interleukin-12 therapeutic use, Interleukin-18 therapeutic use, Interleukin-2 therapeutic use, Lymphocytes metabolism, Macaca mulatta, Male, Mice, Mice, Inbred BALB C, Models, Biological, Prostate-Specific Antigen genetics, T-Lymphocytes metabolism, Time Factors, Cancer Vaccines, Cytokines genetics, Prostatic Neoplasms genetics, Prostatic Neoplasms metabolism, Vaccines, DNA
- Abstract
DNA immunization is an important vaccination technique that is being explored as an immunotherapeutic strategy against a variety of infectious diseases as well as cancer. We have been investigating the utility of DNA-based vaccine strategy against prostate cancer. We have developed a DNA vaccine construct that encodes for the human prostate specific antigen (PSA) gene. PSA expression is limited to prostate cells, and the level of PSA expression is substantially increased in prostate cancer cells. This tissue specificity makes PSA a potential target for the development of immunotherapies against prostate cancer. A DNA-based PSA vaccine was used to elicit PSA-specific host immune responses in rodent and nonhuman primate models. In an effort to enhance the clinical utility of the DNA-based PSA vaccine, we also examined the use of cytokine gene adjuvants to modulate vaccine-induced immune responses in these animal models. We observed that pCPSA vaccine-induced humoral and cellular immune responses can be modulated through the coimmunization with cytokine genes in mice, and these enhancement effects on the PSA-specific cellular responses were extended in macaques. More specifically, coimmunization with interleukin (IL)-2 cDNA construct resulted in a significant enhancement of PSA-specific antibody responses in both mice and macaque models. In contrast, coinjection of IL-12 resulted in reduction of antibody responses in both models. In mice, the groups coimmunized with IL-2, IL-12, or IL-18 showed a dramatic increase in T helper cell proliferation over the results with pCPSA alone. These results support that further evaluation of this vaccination strategy to treat prostate cancer is warranted.
- Published
- 2001
37. Choice of expression vector alters the localization of a human cellular protein.
- Author
-
Ramanathan MP, Ayyavoo V, and Weiner DB
- Subjects
- Active Transport, Cell Nucleus genetics, Amino Acid Sequence, Cell Nucleus genetics, Cell Nucleus metabolism, Cloning, Molecular methods, Gene Products, vpr biosynthesis, Gene Products, vpr genetics, Gene Products, vpr metabolism, Genetic Vectors biosynthesis, Genetic Vectors metabolism, HeLa Cells, Humans, Intracellular Signaling Peptides and Proteins, Ligands, Molecular Sequence Data, RNA-Binding Proteins biosynthesis, Recombinant Fusion Proteins genetics, Recombinant Fusion Proteins metabolism, Recombinant Proteins biosynthesis, Subcellular Fractions metabolism, Genetic Vectors chemical synthesis, Proteins, RNA-Binding Proteins genetics, RNA-Binding Proteins metabolism, Recombinant Fusion Proteins biosynthesis, Recombinant Proteins genetics, Recombinant Proteins metabolism
- Abstract
The fusion of synthetic epitopes with proteins of interest is an important tool in the identification and characterization of recombinant proteins. Several mammalian expression vectors are commercially available containing unique identification tags or epitopes. These vectors offer a great advantage to researchers, as highly specific antibodies and purification resins against these specific epitopes are readily available. The tags facilitate immunologic assays and the purification of the recombinant proteins. The fusion of these epitopes with the recombinant proteins is not expected to alter the behavior of the protein of interest. In this report, we demonstrate that the mere expression of a cellular protein, hVIP/mov34, which we earlier identified as a cellular HIV-1 Vpr ligand, in two different vectors clearly altered its localization pattern in HeLa cells. Specifically, cloning of hVIP/mov34 in pcDNA3/HisA resulted in its nuclear localization, whereas the expression of this gene from a TOPO cloning expression vector, pcDNA3.1/V5/His, resulted in cytoplasmic expression. The native staining pattern of hVIP/mov34 using polyclonal antisera raised against hVIP/mov34 demonstrated cytoplasmic staining. During cloning, other leader sequences intended for targeting this protein into a cytoplasmic or a nuclear location were not fused to the actual ORF of this protein. Also, the amino acid sequence of the fusion region arising from cloning of hVIP/mov34 in both vectors does not match any reported NLS sequences. These results indicate that the choice of the expression vectors, as well as the position of synthetic epitopes, can significantly alter the behavior and the biology of recombinant proteins. This result suggests the need for a careful examination of these features when characterizing a newly identified protein.
- Published
- 2001
- Full Text
- View/download PDF
38. DNA vaccination: antigen presentation and the induction of immunity.
- Author
-
Shedlock DJ and Weiner DB
- Subjects
- Adjuvants, Immunologic, Animals, Antigens genetics, Antigens immunology, Dendritic Cells immunology, Drug Administration Routes, Endocytosis, Forecasting, Gene Expression, Histocompatibility Antigens Class I immunology, Histocompatibility Antigens Class II immunology, Humans, Immune Tolerance, Immunotherapy, Active, Langerhans Cells immunology, Lymph Nodes cytology, Lymph Nodes immunology, Muscle, Skeletal immunology, Plasmids genetics, Reassortant Viruses genetics, Recombinant Fusion Proteins genetics, Recombinant Fusion Proteins immunology, Safety, Transfection, Vaccination methods, Vaccines, DNA therapeutic use, Vaccines, Synthetic immunology, Vaccines, Synthetic therapeutic use, Antigen Presentation, Vaccines, DNA immunology
- Abstract
DNA vaccination, or genetic immunization, is a novel vaccine technology that has great potential for reducing infectious disease and cancer-induced morbidity and mortality worldwide. Since their inception, DNA vaccines have been used to stimulate protective immunity against many infectious pathogens, malignancies, and autoimmune disorders in animal models. Plasmid DNA encoding a polypeptide protein antigen is introduced into a host where it enters host cells and serves as an epigenetic template for the high-efficiency translation of its antigen. An immune response, which is mediated by the cellular and/or humoral arms of the immune system and is specific for the plasmid-encoded antigen, ensues. It is thought that "professional" antigen-presenting cells play a dominant role in the induction of immunity by presenting vaccine peptides on MHC class I molecules, following direct transfection or "cross"-presentation, and MHC class II molecules after antigen capture and processing within the endocytic pathway. The correlates of immunity can be manipulated according to many immunization parameters, including the method of vaccine delivery, presence of genetic adjuvants, and vaccine regimen. DNA vaccines first advanced to the clinic five years ago, and the initial picture of their utility in humans is emerging. However, further analysis is required to determine their ultimate efficacy and safety in human beings. This technology has acquired a strong foothold in the field of experimental immunotherapy, and it is hoped that it will eventually represent the next generation of prophylactic and therapeutic vaccines.
- Published
- 2000
39. DNA vaccines encoding interleukin-8 and RANTES enhance antigen-specific Th1-type CD4(+) T-cell-mediated protective immunity against herpes simplex virus type 2 in vivo.
- Author
-
Sin J, Kim JJ, Pachuk C, Satishchandran C, and Weiner DB
- Subjects
- Animals, Chemokine CCL5 genetics, Cytokines biosynthesis, Female, Immunoglobulin G biosynthesis, Interleukin-8 genetics, Lymphocyte Activation, Mice, Mice, Inbred BALB C, Th2 Cells immunology, Chemokine CCL5 immunology, Herpesvirus 2, Human immunology, Herpesvirus Vaccines immunology, Interleukin-8 immunology, Th1 Cells immunology, Vaccines, DNA immunology, Viral Vaccines immunology
- Abstract
Chemokines are inflammatory molecules that act primarily as chemoattractants and as activators of leukocytes. Their role in antigen-specific immune responses is of importance, but their role in disease protection is unknown. Recently it has been suggested that chemokines modulate immunity along more classical Th1 and Th2 phenotypes. However, no data currently exist in an infectious challenge model system. We analyzed the modulatory effects of selected chemokines (interleukin-8 [IL-8], gamma interferon-inducible protein 10 [IP-10], RANTES, monocyte chemotactic protein 1 [MCP-1], and macrophage inflammatory protein 1 alpha [MIP-1 alpha]) on immune phenotype and protection against lethal challenge with herpes simplex virus type 2 (HSV-2). We observed that coinjection with IL-8 and RANTES plasmid DNAs dramatically enhanced antigen-specific Th1 type cellular immune responses and protection from lethal HSV-2 challenge. This enhanced protection appears to be mediated by CD4(+) T cells, as determined by in vitro and in vivo T-cell subset deletion. Thus, IL-8 and RANTES cDNAs used as DNA vaccine adjuvants drive antigen-specific Th1 type CD4(+) T-cell responses, which result in reduced HSV-2-derived morbidity, as well as reduced mortality. However, coinjection with DNAs expressing MCP-1, IP-10, and MIP-1 alpha increased mortality in the challenged mice. Chemokine DNA coinjection also modulated its own production as well as the production of cytokines. These studies demonstrate that chemokines can dominate and drive immune responses with defined phenotypes, playing an important role in the generation of protective antigen-specific immunity.
- Published
- 2000
- Full Text
- View/download PDF
40. Characterization of a new class of DNA delivery complexes formed by the local anesthetic bupivacaine.
- Author
-
Pachuk CJ, Ciccarelli RB, Samuel M, Bayer ME, Troutman RD, Zurawski DV, Schauer JI, Higgins TJ, Weiner DB, Sosnoski DM, Zurawski VR, and Satishchandran C
- Subjects
- 1-Octanol, Cations, Centrifugation, Density Gradient, DNA administration & dosage, Drug Delivery Systems, Electrophoresis, Agar Gel, Genetic Therapy, Hydrogen-Ion Concentration, Liposomes chemistry, Microscopy, Electron, Scanning, Molecular Structure, Solutions, Transfection, Ultraviolet Rays, Vaccines, DNA, Water, Anesthetics, Local chemistry, Bupivacaine chemistry, DNA chemistry
- Abstract
Bupivacaine, a local anesthetic and cationic amphiphile, forms stable liposomal-like structures upon direct mixing with plasmid DNA in aqueous solutions. These structures are on the order of 50-70 nm as determined by scanning electron microscopy, and are homogeneous populations as analyzed by density gradient centrifugation. The DNA within these structures is protected from nuclease degradation and UV-induced damage in vitro. Bupivacaine:DNA complexes have a negative zeta potential (surface charge), homogeneous nature, and an ability to rapidly assemble in aqueous solutions. Bupivacaine:DNA complexes, as well as similar complexes of DNA with other local anesthetics, have the potential to be a novel class of DNA delivery agents for gene therapy and DNA vaccines.
- Published
- 2000
- Full Text
- View/download PDF
41. Interleukin 7 can enhance antigen-specific cytotoxic-T-lymphocyte and/or Th2-type immune responses in vivo.
- Author
-
Sin JI, Kim J, Pachuk C, and Weiner DB
- Subjects
- Animals, Cell Division, Chemokine CCL2 metabolism, Chemokine CCL5 metabolism, Cytokines metabolism, Female, Gene Expression, Genetic Engineering, Herpes Genitalis immunology, Herpes Genitalis prevention & control, Herpesvirus 2, Human immunology, Humans, Interleukin-10 genetics, Interleukin-10 immunology, Interleukin-12 genetics, Interleukin-12 immunology, Interleukin-7 genetics, Mice, Mice, Inbred BALB C, Plasmids, Th1 Cells cytology, Th1 Cells immunology, Tumor Cells, Cultured, Viral Envelope Proteins genetics, Viral Envelope Proteins immunology, Interleukin-7 immunology, T-Lymphocytes, Cytotoxic immunology, Th2 Cells immunology
- Abstract
Interleukin 7 (IL-7) protein has been reported to be important in the development of cytotoxic-T-lymphocyte (CTL) responses. However, other studies also support a partial Th2 phenotype for this cytokine. In an effort to clarify this unusual conflict, we compared IL-7 along with IL-12 (Th1 control) and IL-10 (Th2 control) for its ability to induce antigen (Ag)-specific CTL and Th1- versus Th2-type immune responses using a well established DNA vaccine model. In particular, IL-7 codelivery showed a significant increase in immunoglobulin G1 (IgG1) levels compared to IgG2a levels. IL-7 coinjection also decreased production of Th1-type cytokine IL-2, gamma interferon, and the chemokine RANTES but increased production of the Th2-type cytokine IL-10 and the similarly biased chemokine MCP-1. In herpes simplex virus (HSV) challenge studies, IL-7 coinjection decreased the survival rate after lethal HSV type 2 (HSV-2) challenge compared with gD plasmid vaccine alone in a manner similar to IL-10 coinjection, whereas IL-12 coinjection enhanced the protection, further supporting that IL-7 drives immune responses to the Th2 type, resulting in reduced protection against HSV-2 challenge. Moreover, coinjection with human immunodeficiency virus type 1 env and gag/pol genes plus IL-12 or IL-7 cDNA enhanced Ag-specific CTLs, while coinjection with IL-10 cDNA failed to influence CTL induction. Thus, IL-7 could drive Ag-specific Th2-type cellular responses and/or CTL responses. These results support that CTLs could be induced by IL-7 in a Th2-type cytokine and chemokine environment in vivo. This property of IL-7 allows for an alternative pathway for CTL development which has important implications for host-pathogen responses.
- Published
- 2000
- Full Text
- View/download PDF
42. HIV-1 Vpr regulates expression of beta chemokines in human primary lymphocytes and macrophages.
- Author
-
Muthumani K, Kudchodkar S, Papasavvas E, Montaner LJ, Weiner DB, and Ayyavoo V
- Subjects
- Chemokines, CC genetics, Gene Expression Regulation, Viral physiology, Gene Products, vpr genetics, Gene Products, vpr pharmacology, Genes, vpr, HIV-1 physiology, HeLa Cells, Humans, Lymphocytes virology, Macrophages virology, Recombinant Proteins pharmacology, Virion genetics, Virion metabolism, Virus Replication physiology, vpr Gene Products, Human Immunodeficiency Virus, Chemokines, CC biosynthesis, Gene Products, vpr physiology, HIV-1 genetics, Lymphocytes metabolism, Macrophages metabolism
- Abstract
The HIV-1 vpr gene encodes a 14-kDa virion-packaged protein that has been implicated in viral pathogenesis. Vpr exhibits profound effects on human primary cells influencing proliferation, differentiation, apoptosis, and cytokine production, in part through NF-kappaB-mediated transcription. NF-kappaB, a potent transcription factor, activates many proinflammatory cytokines/chemokines upon infection. Here, we analyzed the effect of extracellular Vpr as well as the virion-associated Vpr on beta chemokines (MIP-1alpha, MIP-1beta, and RANTES) production in human macrophages and primary lymphocytes (PBLs). Macrophages and PBLs exposed to HIV-1 vpr+ viruses or to recombinant Vpr protein produced significantly less beta chemokines compared with cells infected with HIV-1 vpr-viruses or irrelevant control protein (Gag)-exposed cells. These results suggest that a Vpr-mediated increase in virus replication could be in part through down-regulation of chemokine production.
- Published
- 2000
43. Targeted antigen delivery to antigen-presenting cells including dendritic cells by engineered Fas-mediated apoptosis.
- Author
-
Chattergoon MA, Kim JJ, Yang JS, Robinson TM, Lee DJ, Dentchev T, Wilson DM, Ayyavoo V, and Weiner DB
- Subjects
- Animals, Annexin A5 metabolism, CD8-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes metabolism, Cell Separation, DNA, Complementary metabolism, Dendritic Cells immunology, Dendritic Cells pathology, Enzyme-Linked Immunosorbent Assay, Flow Cytometry, Gene Transfer Techniques, Genetic Therapy methods, Genetic Vectors, Immunohistochemistry, Immunotherapy methods, Interferon-gamma metabolism, Interleukin-12 metabolism, Lymph Nodes metabolism, Male, Mice, Mice, Inbred BALB C, Muscles metabolism, Plasmids metabolism, Spleen cytology, T-Lymphocytes, Cytotoxic immunology, T-Lymphocytes, Cytotoxic pathology, Th1 Cells immunology, Th1 Cells pathology, Time Factors, Transfection, Antigen-Presenting Cells immunology, Antigen-Presenting Cells metabolism, Antigens metabolism, Apoptosis, Dendritic Cells metabolism, fas Receptor metabolism
- Abstract
Immunity to tumors as well as to viral and bacterial pathogens is often mediated by cytotoxic T lymphocytes (CTLs). Thus, the ability to induce a strong cell-mediated immune response is an important requirement of novel immunotherapies. Antigen-presenting cells (APCs), including dendritic cells (DCs), are specialized in initiating T-cell immunity. Harnessing this innate ability of these cells to acquire and present antigens, we sought to improve antigen presentation by targeting antigens directly to DCs in vivo through apoptosis. We engineered Fas-mediated apoptotic death of antigen-bearing cells in vivo by co-expressing the immunogen and Fas in the same cell. We then observed that the death of antigen-bearing cells results in increased antigen acquisition by APCs including DCs. This in vivo strategy led to enhanced antigen-specific CTLs, and the elaboration of T helper-1 (Th1) type cytokines and chemokines. This adjuvant approach has important implications for viral and nonviral delivery strategies for vaccines or gene therapies.
- Published
- 2000
- Full Text
- View/download PDF
44. Therapeutic immunization of HIV-infected chimpanzees using HIV-1 plasmid antigens and interleukin-12 expressing plasmids.
- Author
-
Boyer JD, Cohen AD, Ugen KE, Edgeworth RL, Bennett M, Shah A, Schumann K, Nath B, Javadian A, Bagarazzi ML, Kim J, and Weiner DB
- Subjects
- Animals, CD4-Positive T-Lymphocytes cytology, CD4-Positive T-Lymphocytes immunology, Cell Division, Consumer Product Safety, Disease Models, Animal, Genes, env immunology, Genes, gag immunology, Genes, pol immunology, HIV Antibodies immunology, HIV Antigens immunology, HIV Envelope Protein gp120 immunology, HIV Infections blood, HIV Infections immunology, Humans, Interleukin-12 genetics, Pan troglodytes, Vaccination methods, Viral Load, AIDS Vaccines immunology, DNA, Viral immunology, HIV Antigens genetics, HIV Infections therapy, HIV-1 immunology, Interleukin-12 immunology, Plasmids immunology, Vaccines, DNA immunology
- Abstract
Objective: To assess HIV-1 DNA vaccination and co-immunization with interleukin (IL)-12 and IL-10 as immunotherapy in the HIV-1 infected chimpanzee model system., Methods: Four chimpanzees that were infected with HIV-1-IIIB for longer than 4 years and remained symptom free were immunized with HIV-1 plasmid vaccines. Two chimpanzees were immunized with DNA plasmids that encoded env/rev, gag/pol along with a plasmid that encoded both chains of human IL-12. A third animal was immunized with HIV-1 DNA vaccine constructs and co-immunized with an IL-10 expressing plasmid. Finally a control animal received the HIV-1 DNA vaccine constructs alone., Results: There was no evidence of systemic toxicity associated with the administration of the DNA vaccines or the cytokine-expressing plasmids. We observed that the IL-12/HIV-1 DNA vaccinated animals had enhanced proliferative responses to multiple HIV-1 antigens at multiple time points. The animal that was co-immunized with HIV-1 and IL-10 did not have any changes in the proliferative responses. Finally, the control chimpanzee demonstrated moderate increases in the proliferative responses to HIV-1 antigens. The animal that received HIV-1 vaccines alone and the animals co-immunized with IL-12 all had declines in viral load over the course of the study, however, the decrease in viral loads were transient in all animals., Conclusion: Immunization of HIV-1 infected chimpanzees with DNA based vaccines containing the env, gag and pol genes can transiently boost the env specific proliferative responses. Co-administration of IL-12 expressing plasmids further leads to transient boosting of the proliferative response to the core protein, p24 as well. However, at these doses the impact on viral load is minimal.
- Published
- 2000
- Full Text
- View/download PDF
45. Cutting edge: DNA immunization with minigenes of carbohydrate mimotopes induce functional anti-carbohydrate antibody response.
- Author
-
Kieber-Emmons T, Monzavi-Karbassi B, Wang B, Luo P, and Weiner DB
- Subjects
- Amino Acid Sequence, Animals, Antibody-Dependent Cell Cytotoxicity, Carbohydrates administration & dosage, Carbohydrates genetics, Cross Reactions genetics, Epitopes, T-Lymphocyte administration & dosage, Epitopes, T-Lymphocyte genetics, Humans, Immunoglobulin G physiology, Injections, Intramuscular, Injections, Intraperitoneal, Lewis Blood Group Antigens administration & dosage, Lewis Blood Group Antigens genetics, Lewis Blood Group Antigens immunology, Lymphocyte Activation, Mice, Mice, Inbred BALB C, Molecular Sequence Data, Peptides genetics, Peptides immunology, Plasmids administration & dosage, Plasmids genetics, Plasmids immunology, T-Lymphocytes immunology, Tumor Cells, Cultured, Vaccines, DNA administration & dosage, Carbohydrates immunology, Epitopes, T-Lymphocyte immunology, Immunoglobulin G biosynthesis, Molecular Mimicry, Vaccines, DNA immunology
- Abstract
To date, the generation of anti-carbohydrate Th1 immune responses, which would be useful for both tumor immunotherapy as well as in pathogen vaccine strategies, has been elusive. To augment Th1 immune responses to carbohydrate Ags, we describe results of DNA vaccination studies in mice using plasmids encoding designed peptide mimotopes (minigenes) of the neolactoseries Ag Lewis Y (LeY). In contrast to LeY immunization, immunization with mimotope-encoded plasmids induced LeY cross-reactive IgG2a Abs. Minigene immunization primed for a LeY-specific response that is rapidly activated upon encounter with nominal Ag upon subsequent boost. The resulting IgG2a response mediated complement-dependent cytotoxicity of a LeY-expressing human tumor cell line in the presence of human complement. These studies establish that peptide mimotopes of carbohydrate Ags encoded as DNA plasmids are novel immunogens providing a means to manipulate carbohydrate cross-reactive Th1 responses.
- Published
- 2000
- Full Text
- View/download PDF
46. LFA-3 plasmid DNA enhances Ag-specific humoral- and cellular-mediated protective immunity against herpes simplex virus-2 in vivo: involvement of CD4+ T cells in protection.
- Author
-
Sin JI, Kim J, Dang K, Lee D, Pachuk C, Satishchandran C, and Weiner DB
- Subjects
- Animals, Antigen Presentation, CD58 Antigens immunology, Chemokines, CC biosynthesis, Female, Herpes Genitalis mortality, Immunoglobulin Isotypes, Intercellular Adhesion Molecule-1 immunology, Interferon-gamma biosynthesis, Interleukins biosynthesis, Mice, Mice, Inbred BALB C, T-Lymphocyte Subsets immunology, Th1 Cells immunology, Th2 Cells immunology, Vaccines, DNA therapeutic use, Vagina immunology, CD4-Positive T-Lymphocytes immunology, CD58 Antigens therapeutic use, Herpes Genitalis prevention & control, Herpesvirus 2, Human immunology, Immunity, Cellular, Immunoglobulin G biosynthesis, Viral Vaccines therapeutic use
- Abstract
Adhesion molecules are important for cell trafficking and delivery of secondary signals for stimulation of T cells and antigen-presenting cells (APCs) in a variety of immune and inflammatory responses. Adhesion molecules lymphocyte function-associated antigen (LFA)-1 and CD2 on T cells recognize intercellular adhesion molecule (ICAM)-1 and LFA-3 on APCs, respectively. Recent studies have suggested that these molecules might play a regulatory role in antigen-specific immune responses. To investigate specific roles of adhesion molecules in immune induction we coimmunized LFA-3 and ICAM-1 cDNAs with a gD plasmid vaccine and then analyzed immune modulatory effects and protection against lethal herpes simplex virus (HSV)-2 challenge. We observed that gD-specific IgG production was enhanced by LFA-3 coinjection. However, little change in IgG production was observed by ICAM-1 coinjection. Furthermore, both Th1 and Th2 IgG isotype production was driven by LFA-3. LFA-3 also enhanced Th cell proliferative responses and production of interleukin (IL)-2, interferon-gamma, IL-4, and IL-10 from splenocytes. In contrast, ICAM-1 showed slightly increasing effects on T-cell proliferation responses and cytokine production. beta-Chemokine production (RANTES, MIP-1alpha, and MCP-1) was also influenced by LFA-3 or ICAM-1. When animals were challenged with a lethal dose of HSV-2, LFA-3-coimmunized animals exhibited an enhanced survival rate, as compared to animals given ICAM-1 or gD DNA vaccine alone. This enhanced protection appears to be mediated by CD4+ T cells, as determined by in vitro and in vivo T-cell subset deletion. These studies demonstrate that adhesion molecule LFA-3 can play an important role in generating protective antigen-specific immunity in the HSV model system through increased induction of CD4+ Th1 T-cell subset., (Copyright 2000 Academic Press.)
- Published
- 2000
- Full Text
- View/download PDF
47. Chemokine gene adjuvants can modulate immune responses induced by DNA vaccines.
- Author
-
Kim JJ, Yang JS, Dentchev T, Dang K, and Weiner DB
- Subjects
- Animals, Antibody Formation, Chemokine CCL3, Chemokine CCL4, Chemokine CCL5 genetics, Cytokines genetics, Female, Gene Expression, Immunization, Interleukin-8 genetics, Lymphocyte Activation, Macrophage Inflammatory Proteins genetics, Mice, Mice, Inbred BALB C, T-Lymphocytes, Cytotoxic immunology, T-Lymphocytes, Helper-Inducer immunology, Vaccines, DNA genetics, Chemokines genetics, Vaccines, DNA pharmacology
- Abstract
Nucleic acid immunization has been shown to induce both antigen-specific cellular and humoral immune responses in vivo. Moreover, immune responses induced by DNA immunization can be enhanced by the use of molecular adjuvants. For example, coadministration of costimulatory molecules (CD80 and CD86), proinflammatory cytokines (interleukin-1alpha [IL-1alpha], tumor necrosis factor-alpha [TNF-alpha, and TNF-beta), Th1 cytokines (interleukin-2 [IL-2], IL-12, IL-15, and IL-18), Th2 cytokines (IL-4, IL-5, and IL-10), and granulocytes-macrophage colony-stimulating factor (GM-CSF) with DNA vaccine constructs leads to modulation of the magnitude and direction (humoral or cellular) of the immune responses. To further engineer the immune response in vivo, we compared the induction and regulation of immune responses from the codelivery of chemokine (IL-8, interferon-gamma-inducible protein-10 [gammaIP-10], macrophage inhibitory protein-1alpha [MIP-1alpha], and RANTES) genes with codelivery of cytokine genes. We found that as in cytokine gene codelivery, coimmunization with chemokine genes along with DNA immunogen constructs can modulate the direction and magnitude of induced immune responses. We observed that coimmunization with IL-8, gammaIP-10, and MIP-1alpha genes increased the antibody response. We also found that coinjection with IL-8, gammaIP-10, and RANTES resulted in a dramatic enhancement of T helper (Th) proliferation response. Furthermore, among all coinjection combinations, we found that RANTES coinjection caused a high level of cytotoxic lymphocyte (CTL) enhancement. This enhancement of CTL responses observed from the coinjection with RANTES was CD8+ T cell dependent. Together with earlier reports on the utility of coimmunizing immunologically important molecules with DNA immunogens, we demonstrate the potential of this strategy as an important tool for the development of more rationally designed vaccines.
- Published
- 2000
- Full Text
- View/download PDF
48. Characterization of a novel human immunodeficiency virus type 1 neutralizable epitope within the immunodominant region of gp41.
- Author
-
Viveros M, Dickey C, Cotropia JP, Gevorkian G, Larralde C, Broliden K, Levi M, Burgess A, Cao C, Weiner DB, Agadjanyan MG, and Ugen KE
- Subjects
- Amino Acid Sequence, Amino Acid Substitution, Animals, Antibodies, Monoclonal immunology, Antibody Specificity immunology, Cell Line, Cysteine immunology, Cysteine metabolism, Disulfides immunology, Disulfides metabolism, HIV Antigens chemistry, HIV Envelope Protein gp160 immunology, HIV Envelope Protein gp41 chemistry, HIV Seropositivity immunology, HIV Seropositivity virology, HIV-1 genetics, HIV-1 physiology, Humans, Immune Sera immunology, Immunodominant Epitopes chemistry, Molecular Sequence Data, Neutralization Tests, Peptides, Cyclic chemical synthesis, Peptides, Cyclic chemistry, Peptides, Cyclic immunology, Rabbits, Virus Replication, HIV Antigens immunology, HIV Envelope Protein gp41 immunology, HIV-1 immunology, Immunodominant Epitopes immunology
- Abstract
Previously, we generated human monoclonal antibodies using peripheral blood mononuclear cells from an asymptomatic human immunodeficiency virus type 1 (HIV-1)-seropositive donor. One of these monoclonal antibodies (designated clone 3, CL3) recognized 10 amino acids (GCSGKLICTT) within the immunodominant region (cluster I) of the transmembrane envelope glycoprotein gp41 and neutralized infection of target cells with different laboratory isolates. Because the epitope recognized by CL3 has two cysteine residues that could potentially produce a disulfide loop in gp41, we analyzed binding of our monoclonal antibody to the cyclic and linear motif of the peptide sequence IWGCSGKLICTTAVP (residues 600-614). The CL3 antibody did not bind to the synthetic cyclic peptide but did recognize the linear form. Two polyclonal rabbit sera against both the linear and cyclic peptides were then generated. Both antisera bound to viral glycoproteins gp41 and gp160, but neither sera neutralized HIV-1 laboratory isolates. Using a set of alanine-substituted IWGCSGKLICTTAV peptides, we analyzed binding of polyclonal antisera and CL3. The profile of binding of polyclonal antisera to these peptides was different from that of CL3 to the same peptides. This suggests that CL3 recognized a unique neutralizable core epitope, which was not immunogenic in either the cyclic or the linear IWGCSGKLICTTAVP peptides used as immunogens in the rabbits., (Copyright 2000 Academic Press.)
- Published
- 2000
- Full Text
- View/download PDF
49. Murine monoclonal antibodies biologically active against the amino region of HIV-1 gp120: isolation and characterization.
- Author
-
Dickey C, Ziegner U, Agadjanyan MG, Srikantan V, Refaeli Y, Prabhu A, Sato A, Williams WV, Weiner DB, and Ugen KE
- Subjects
- Amino Acid Sequence, Animals, Antibody-Dependent Cell Cytotoxicity, Enzyme-Linked Immunosorbent Assay, Epitope Mapping, HIV Envelope Protein gp120 chemistry, Humans, Mice, Mice, Inbred BALB C, Molecular Sequence Data, Precipitin Tests, Antibodies, Monoclonal immunology, Epitopes immunology, HIV Envelope Protein gp120 immunology, HIV-1 immunology
- Abstract
The human immunodeficiency virus (HIV)-1 envelope glycoprotein is synthesized as a precursor (gp160) and subsequently cleaved to generate the external gp120 and transmembrane gp41 glycoproteins. Both gp120 and gp41 have been demonstrated to mediate critical functions of HIV, including viral attachment and fusion with the cell membrane. The antigenic variability of the HIV-1 envelope glycoprotein has presented a significant problem in the design of appropriate and successful vaccines and offers one explanation for the ability of HIV to evade immune surveillance. Therefore, the development and characterization of functional antibodies against conserved regions of the envelope glycoprotein is needed. Because of this need, we generated a panel of murine monoclonal antibodies (MuMabs) against the HIV-1 envelope glycoprotein. To accomplish this, we immunized Balb/C mice with a recombinant glycoprotein 160 (gp160) that was synthesized in a baculovirus expression system. From the growth-positive hybridomas, three MuMabs were generated that demonstrated significant reactivity with recombinant gp120 but failed to show reactivity against HIV-1 gp41, as determined by enzyme-linked immunosorbent assay (ELISA). Using vaccinia constructs that synthesize variant truncated subunits of gp160, we were able to map reactivity of all three of the Mabs (ID6, AC4, and AD3) to the first 204 residues of gp120 (i.e., the N terminus of gp120) via Western blot analysis. Elucidation of the epitopes for these Mabs may have important implications for inhibition of infection by HIV-1. Our initial attempts to map these Mabs with linear epitopes have not elucidated a specific antigenic determinant; however, several physical characteristics have been determined that suggest a continuous surface epitope. Although these antibodies failed to neutralize cell-free or cell-associated infection by HIV-1, they did mediate significant antibody-dependent cellular cytotoxicity (ADCC) activity, indicating potential therapeutic utility. In summary, these data suggest the identification of a potentially novel site in the first 200 aa of gp120 that mediates ADCC.
- Published
- 2000
- Full Text
- View/download PDF
50. Modulation of antigen-specific humoral responses in rhesus macaques by using cytokine cDNAs as DNA vaccine adjuvants.
- Author
-
Kim JJ, Yang JS, VanCott TC, Lee DJ, Manson KH, Wyand MS, Boyer JD, Ugen KE, and Weiner DB
- Subjects
- Animals, Humans, Macaca mulatta, Adjuvants, Immunologic administration & dosage, Antibodies, Viral biosynthesis, Antigens, Viral immunology, Cytokines genetics, DNA, Complementary immunology, Viral Vaccines immunology
- Abstract
An important limitation of DNA immunization in nonhuman primates is the difficulty in generating high levels of antigen-specific antibody responses; strategies to enhance the level of immune responses to DNA immunization may be important in the further development of this vaccine strategy for humans. We approached this issue by testing the ability of molecular adjuvants to enhance the levels of immune responses generated by multicomponent DNA vaccines in rhesus macaques. Rhesus macaques were coimmunized intramuscularly with expression plasmids bearing genes encoding Th1 (interleukin 2 [IL-2] and gamma interferon)- or Th2 (IL-4)-type cytokines and DNA vaccine constructs encoding human immunodeficiency virus Env and Rev and simian immunodeficiency virus Gag and Pol proteins. We observed that the cytokine gene adjuvants (especially IL-2 and IL-4) significantly enhanced antigen-specific humoral immune responses in the rhesus macaque model. These results support the assumption that antigen-specific responses can be engineered to a higher and presumably more desirable level in rhesus macaques by genetic adjuvants.
- Published
- 2000
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.